Department of Urology, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou 510120, China.
Chin J Integr Med. 2013 Aug;19(8):589-95. doi: 10.1007/s11655-012-1233-5. Epub 2012 Dec 3.
To explore the mechanisms of Chinese herbal medicine Sanqi Oral Liquid, composed of Astragalus membranaceus and Panpax notoginseng, in alleviating renal injury by observing its effect on the expressions of CD4(+), CD8(+) and CD68(+) cells in 5/6 nephrectomized rats with chronic renal failure.
A total of 102 SD rats were randomly divided into six groups: three treatment groups were administrated with high, medium and low dosage of Sanqi Oral Liquid respectively by gavage; a normal group, a 5/6 nephrectomized model group, and a group treated with coated aldehyde oxygenstarch were used as controls. Following oral administration of Sanqi Oral Liquid for 12 weeks, the general condition and renal pathological changes were observed, and the renal function, platelet count (PLT) and the expressions of CD4(+), CD8(+) and CD68(+) cells were determined for each group.
There were proliferation of mesangial matrix, renaltubularnecrosis and obvious tubulointerstitial fibrosis in the model group, and they were much milder in the treatment groups. Compared with the model group, the amounts of blood urea nitrogen (BUN), serum creatinine (Scr) and PLT in the treatment groups decreased (P<0.05 for all); and in the group administrated of medium dosage of Sanqi Oral Liquid, the expression of CD4(+) cells was up-regulated and those of CD8(+) and CD68(+) cells were down-regulated (P<0.05 for all), leading to an increased ratio of CD4(+)/CD8(+)(P<0.01).
Sanqi Oral Liquid has a significant effect on regulating lymphocyte subsets, reducing the infiltration of macrophages in renal tissues and alleviating tubulointerstitial fibrosis, and this may be one of mechanisms of Sanqi Oral Liquid in delaying the progression of chronic kidney diseases.
观察复方三七口服液(含黄芪、三七)对 5/6 肾切除慢性肾衰竭大鼠 CD4+、CD8+、CD68+细胞表达的影响,探讨其减轻肾损伤的作用机制。
102 只 SD 大鼠随机分为 6 组,分别灌胃给予高、中、低剂量复方三七口服液,另设正常组、5/6 肾切除模型组、醛氧化淀粉对照组,连续给药 12 周后观察一般情况及肾脏病理变化,检测各组大鼠肾功能、血小板计数(PLT)及 CD4+、CD8+、CD68+细胞表达。
模型组大鼠系膜基质增生,肾小管坏死,肾间质纤维化明显,各治疗组大鼠病变均较模型组减轻。与模型组比较,各治疗组大鼠血尿素氮(BUN)、血清肌酐(Scr)、PLT 降低(P<0.05);中剂量组大鼠 CD4+细胞表达上调,CD8+、CD68+细胞表达下调(P<0.05),CD4+/CD8+比值升高(P<0.01)。
复方三七口服液能调节淋巴细胞亚群,减少肾组织巨噬细胞浸润,减轻肾小管间质纤维化,这可能是其延缓慢性肾脏病进展的作用机制之一。